Contact Us
Contact Us

Metabolic & Endocrinology CRO

Clinical Development Support for Metabolic and Endocrine Diseases

Guided by a science-first approach, Lotus brings efficiency and experience to your clinical development programs. As a specialized CRO with a focus on metabolic and endocrine clinical research, including Obesity, our experts across the medical, operational, site, and support functions ensure your studies are prioritized and streamlined from early through later phases.

0 +
Metabolic Studies Conducted
0 +
Diabetes Studies Conducted
0 +
Obesity Studies Conducted
0
MASH/NAFLD Studies Conducted

FibroScan, MRI, Biopsies Present in Many Trials

Statistics combine experience from both Lotus Clinical Research and Evolution Research Group’s network of clinical research sites.

Let us put our experience in metabolic and endocrine clinical development to work for you.

Talk to our Experts
Dive Deeper into Obesity

The Lotus Difference in Metabolic and Endocrine Clinical Development

Faster Site Activation

With priority access to Evolution Research Group’s (ERG) highly sought-after US-based sites, we can accelerate study startup with unparalleled operational efficiencies.

~160K participant profiles

Our in-house team actively refreshes and recruits from our expanding database of overweight and obese individuals. Our “Every Body Research” initiative provides a rich database of volunteers and patients to jump-start your trial.

Industry-leading Experts

Known for our scientific rigor, our Scientific Leadership Team (SLT) includes some of the industry’s leading experts in obesity and metabolic research.

Early Phase

Derisking an early phase product is a critical first step. Our experts can support proof of concept, proof of mechanism, and specialized testing in our Phase I Clinical Pharmacology Units.

Learn More +
Foundation for the National Institute of Health (FNIH) Biomarkers Consortium

With membership in the FNIH Biomarkers Consortium and representation on the Metabolic Diseases Steering Committee, our subject matter experts are at the forefront of supporting these crucial development programs.

Obesity Task Force
This multi-disciplinary team from Lotus and ERG integrates scientific, medical, and operational expertise, including patient access. These metabolic experts are actively involved in guiding your study throughout its duration.

Learn More +

With science always at the forefront, our metabolic experts remain part of the project team throughout the study’s duration.

Specialized Phase I Units Supporting a Full Spectrum of Clinical Pharmacology Studies

Our dedicated Phase I Units offer over 400 beds and 20+ years of experience involving healthy volunteers and special populations. Our experience spans a broad range of clinical pharmacology studies including:

  • First-in-human (FIH)
  • Pharmacokinetics/pharmacodynamics (PK/PD)
  • Single and multiple ascending doses (SAD/MAD)
  • Drug-drug interactions (DDI)
  • Bioequivalence/bioavailability (BE/BA)
  • Human Abuse Potential (HAP)
  • Food Effect
  • QTc/TQT interval
  • First to File studies

Advanced Testing Methods

Many of these studies have required overnight stays of up to 60 days and have incorporated advanced testing methods including:
  • Glucose Clamps
  • Oral Glucose and Mixed Meal Tolerance Testing
  • Intravenous Glucose Tolerance Testing
  • Insulin Tolerance Testing
  • Maximum Pancreatic Stimulation Tests
  • Graded Glucose Infusions
  • Stable Isotope Dilution Methods
  • De Novo Lipogenesis Testing
  • Gastric Emptying by multiple modalities
  • Universal Eating Monitor (UEM)
  • Flow Mediated Dilation (FMD)
  • Indirect Calorimetry
  • Dual-energy X-ray absorptiometry (DEXA or DXA)
  • Magnetic resonance imaging (MRI)
  • Ultrasonography
  • FibroScan®
  • Biopsy (Liver, Adipose, Muscle, etc)
  • Peripheral blood mononuclear cell (PBMC) collections
  • Electroencephalography (EEG)
  • Spot and serial cerebrospinal fluid (CSF) collections
Our expertise at the intersection of Metabolic, CNS, and comorbid conditions drives smarter, faster trials.

From Neuroscience to Metabolic and Obesity

Over the past decade, Lotus and ERG have evolved from a foundation in CNS-related clinical development into the broader metabolic landscape, including obesity. Our early work in psychiatry and neurology positioned us to understand complex central mechanisms; experience that’s increasingly relevant as obesity treatments shift toward centrally acting therapies. From there, we expanded into metabolic research through diabetes, fatty liver disease, and other comorbid conditions across our renal and hepatic centers.

Contact for Inquiries